New Enterprise Associates 16, L.P.'s Net Worth
$38.1 Million
Who is New Enterprise Associates 16, L.P.?
New Enterprise Associates 16, L.P. has an estimated net worth of $38.1 Million. This is based on reported shares across multiple companies, which include Mirum Pharmaceuticals, Inc., GENOCEA BIOSCIENCES, INC., Metacrine, Inc., Trevi Therapeutics, Inc., Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Regulus Therapeutics Inc., and Marker Therapeutics, Inc..
SEC CIK
New Enterprise Associates 16, L.P.'s CIK is 0001694560
Past Insider Trading and Trends
2019 was New Enterprise Associates 16, L.P.'s most active year for acquiring shares with 13 total transactions. New Enterprise Associates 16, L.P.'s most active month to acquire stocks was the month of April. 2020 was New Enterprise Associates 16, L.P.'s most active year for disposing of shares, totalling 7 transactions. New Enterprise Associates 16, L.P.'s most active month to dispose stocks was the month of May. 2019 saw New Enterprise Associates 16, L.P. paying a total of $58,338,581.88 for 38,924,291 shares, this is the most they've acquired in one year. In 2022 New Enterprise Associates 16, L.P. cashed out on 14,671,143 shares for a total of $750,662.12, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Mirum Pharmaceuticals, Inc. (MIRM) Snapshot price: $26.82
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -47.78% | -2.00M |
—
|
—
| 2.19M |
Jun 13
| |||
Form 4
|
∞
| 4.19M |
$15.00 |
—
| 4.19M |
Jul 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GENOCEA BIOSCIENCES, INC. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -10.38M |
$0.07 | -$750,662.12 |
0
|
May 24 - May 25
| |||
Form 4
| +43.61% | 3.15M |
$2.25 | $7,090,335.00 | 10.38M |
Jul 24
| |||
Form 4
| +65.40% | 2.86M |
$3.50 | $9,999,997.00 | 7.23M |
Jun 24
| |||
Form 4
| +39.79% | 9.95M |
$0.47 | $4,688,619.18 | 34.95M |
Feb 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Metacrine, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -16.25% | -497.27K |
$0.99 | -$494,482.97 | 2.56M |
Dec 10 - Dec 22
| |||
Form 4
|
∞
| 3.06M |
$13.00 |
—
| 3.06M |
Sep 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Trevi Therapeutics, Inc. (TRVI) Snapshot price: $1.42
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +33.78% | 2.63M |
$1.90 | $4,999,998.20 | 10.42M |
Apr 11
| |||
Form 4
| +31.19% | 1.85M |
—
|
—
| 7.79M |
Oct 18
| |||
Form 4
| +33.78% | 1.5M |
$2.66 | -$0.24 | 5.94M |
Apr 3
| |||
Form 4
|
∞
| 4.44M |
$10.00 |
—
| 4.44M |
May 9
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Akouos, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -4.29M |
—
|
—
|
0
|
Nov 30
| |||
Form 4
|
∞
| 4.29M |
$17.00 |
—
| 4.29M |
Jun 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||